⚠ Emergency: ElinMed does not provide emergency services. Call 911 immediately.
Now accepting virtual patients  ·  In-person Midtown East flagship opening Fall 2026
⚠ Emergency: ElinMed does not provide emergency services. If experiencing chest pain or severe symptoms, call 911 immediately.
🔥 PDF Prevention Guide · $37

Inflammation & Heart Disease: The Prevention Frontier

The CANTOS trial changed cardiology's understanding of residual cardiovascular risk. This guide covers the inflammatory basis of atherosclerosis, biomarkers Dr. Nyange measures to assess it, chronic inflammatory diseases as cardiac risk factors, and the anti-inflammatory interventions with the strongest evidence — including colchicine.

✓ 6 pages✓ CANTOS trial explained✓ Biomarker guide✓ hsCRP interpretation✓ PDF download
$37
One-time purchase · Instant PDF download
  • 6-stage inflammatory atherosclerosis progression
  • hsCRP, Lp(a), IL-6, fibrinogen, MPO — what each measures
  • RA, psoriasis, SLE, IBD, OSA as cardiac risk factors
  • Colchicine (LoDoCo2, COLCOT) — the new anti-inflammatory cardiac drug
  • Mediterranean diet anti-inflammatory mechanisms
  • Statins' pleiotropic inflammation effects (JUPITER trial)
Get Inflammation Prevention Guide — $37
🔒 Secure📚 Instant download💳 One-time
The other half of cardiovascular risk

50% of cardiovascular events occur in patients with LDL already at target. Inflammation is why.

Statins work. But they do not eliminate cardiovascular risk — they reduce LDL-driven risk. Patients with LDL of 50 who are still having events are telling us something important: there is a second pathway, and it runs through inflammation. The CANTOS trial proved this by showing that blocking inflammation (without touching cholesterol) significantly reduces cardiac events.

This guide explains the inflammatory biology of atherosclerosis, the biomarkers that measure it, the chronic diseases that drive it, and the expanding toolkit — from Mediterranean diet to colchicine — for targeting it.

By the numbers

What’s inside

50%
Residual Risk
Of cardiovascular events occur in patients with LDL already at target — driven substantially by inflammation
37%
CV Death Drop
Reduction in cardiovascular deaths in CANTOS trial's highest hsCRP responders treated with anti-IL-1beta therapy
6
Stages
From endothelial injury to plaque rupture — inflammation is present at every stage of atherosclerosis

“The CANTOS trial changed how I think about residual cardiovascular risk. We have patients on maximum statin therapy with LDL of 50 who still have events — and their hsCRP is 4 or 5. That is inflammatory residual risk, and it is now a therapeutic target. Colchicine, lifestyle, Mediterranean diet — we have tools. Measuring hsCRP is where it starts.”

CN
Dr. Christabel Nyange, MD, MPH, FACC
Founder, ElinMed · Board-Certified Cardiologist
FAQ

Common Questions

My LDL is well controlled on statins. Do I still need to worry about inflammation?
Yes — this is exactly the clinical question the CANTOS trial addressed. When patients with controlled LDL (and elevated hsCRP) were treated with an anti-inflammatory drug that didn't change cholesterol, they had significantly fewer cardiac events. This suggests that residual inflammatory risk is a real, targetable entity beyond LDL. Checking your hsCRP alongside your LDL gives a more complete picture. If your hsCRP remains elevated despite statin therapy, there are now specific interventions — including low-dose colchicine — with RCT evidence.
What is colchicine and why is it being used for heart disease?
Colchicine is an anti-inflammatory drug used for decades in gout. Its cardiovascular application emerged from recognizing that NLRP3 inflammasome activation (which colchicine blocks) is a key driver of residual cardiovascular inflammation. The COLCOT trial (post-MI) and LoDoCo2 trial (stable CAD) both showed ~23-31% reduction in recurrent cardiovascular events with low-dose colchicine 0.5 mg daily. It is now recommended by ACC/AHA guidelines as an adjunct therapy in patients with recurrent events or elevated inflammatory markers on optimal medical therapy.
I have rheumatoid arthritis. Does that affect my heart?
Yes, significantly. Rheumatoid arthritis is associated with approximately 2-fold elevated cardiovascular risk — a magnitude comparable to type 2 diabetes. TNF-alpha and IL-6 from synovial inflammation drive systemic atherosclerosis, not just joint damage. Importantly, treating RA aggressively with DMARDs and biologics reduces cardiovascular risk — anti-inflammatory treatment for RA is simultaneously cardiac treatment. Every RA patient should have explicit cardiovascular risk assessment and management as part of their care.

Cardiovascular prevention beyond cholesterol.

The inflammation guide for patients who want to understand their complete cardiac risk.

Get Inflammation Prevention Guide — $37
← Back to all resources